You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDasatinib
Accession NumberDB01254
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
Structure
Thumb
Synonyms
anh. dasatinib
Anhydrous dasatinib
BMS dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
External Identifiers
  • BMS-354825
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SprycelTablet, film coated20 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet70 mg/1OralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
SprycelTablet70 mg/1OralPhysicians Total Care, Inc.2007-02-12Not applicableUs
SprycelTablet, film coated70 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet80 mg/1OralE.R. Squibb & Sons, L.L.C.2010-10-28Not applicableUs
SprycelTablet, film coated50 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated80 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet100 mgOralBristol Myers Squibb Canada2009-05-04Not applicableCanada
SprycelTablet, film coated50 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet20 mg/1OralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
SprycelTablet20 mgOralBristol Myers Squibb Canada2007-04-13Not applicableCanada
SprycelTablet, film coated100 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet140 mg/1OralE.R. Squibb & Sons, L.L.C.2010-10-28Not applicableUs
SprycelTablet, film coated70 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated140 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet80 mgOralBristol Myers Squibb Canada2011-09-02Not applicableCanada
SprycelTablet, film coated70 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet50 mg/1OralE.R. Squibb & Sons, L.L.C.2006-06-27Not applicableUs
SprycelTablet50 mgOralBristol Myers Squibb Canada2007-04-13Not applicableCanada
SprycelTablet, film coated100 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated20 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet140 mgOralBristol Myers Squibb Canada2011-03-29Not applicableCanada
SprycelTablet, film coated140 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated20 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet100 mg/1OralE.R. Squibb & Sons, L.L.C.2008-05-30Not applicableUs
SprycelTablet70 mgOralBristol Myers Squibb Canada2007-04-13Not applicableCanada
SprycelTablet, film coated80 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
SprycelTablet, film coated50 mgOralBristol Myers Squibb Pharma Eeig2006-11-20Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dasatinib monohydrate
863127-77-9
Thumb
  • InChI Key: XHXFZZNHDVTMLI-UHFFFAOYSA-N
  • Monoisotopic Mass: 505.1662867
  • Average Mass: 506.02
DBSALT001849
Categories
UNIIX78UG0A0RN
CAS number302962-49-8
WeightAverage: 488.006
Monoisotopic: 487.155721508
Chemical FormulaC22H26ClN7O2S
InChI KeyZBNZXTGUTAYRHI-UHFFFAOYSA-N
InChI
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
IUPAC Name
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
SMILES
CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Pharmacology
IndicationFor the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
Structured Indications
PharmacodynamicsDasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor
Mechanism of actionDasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tyrosine-protein kinase ABL1Proteinyes
multitarget
HumanP00519 details
Proto-oncogene tyrosine-protein kinase SrcProteinyes
multitarget
HumanP12931 details
Ephrin type-A receptor 2Proteinyes
antagonist
HumanP29317 details
Tyrosine-protein kinase LckProteinyes
multitarget
HumanP06239 details
Tyrosine-protein kinase YesProteinyes
inhibitor
HumanP07947 details
Mast/stem cell growth factor receptor KitProteinunknown
antagonist
HumanP10721 details
Platelet-derived growth factor receptor betaProteinunknown
antagonist
HumanP09619 details
Signal transducer and activator of transcription 5BProteinunknown
inhibitor
HumanP51692 details
Abelson tyrosine-protein kinase 2Proteinunknown
multitarget
HumanP42684 details
Tyrosine-protein kinase FynProteinunknown
multitarget
HumanP06241 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 2505 L
Protein binding96%
Metabolism

Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4

Route of eliminationDasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4. Elimination is primarily via the feces.
Half lifeThe overall mean terminal half-life of dasatinib is 3-5 hours.
ClearanceNot Available
ToxicityAcute overdose in animals was associated with cardiotoxicity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabDasatinib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Dasatinib can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Dasatinib.Approved
AcenocoumarolDasatinib may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenAcetaminophen may increase the hepatotoxic activities of Dasatinib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Dasatinib.Approved
Acetylsalicylic acidDasatinib may increase the anticoagulant activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Dasatinib.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dasatinib.Approved
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Dasatinib.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Dasatinib.Approved
AldosteroneThe serum concentration of Dasatinib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Dasatinib can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Dasatinib.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Dasatinib.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Dasatinib.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dasatinib.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Dasatinib.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Dasatinib.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Dasatinib.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Dasatinib.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational
AlprostadilDasatinib may increase the anticoagulant activities of Alprostadil.Approved, Investigational
ALT-110The risk or severity of adverse effects can be increased when Dasatinib is combined with ALT-110.Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe serum concentration of Dasatinib can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Dasatinib.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Dasatinib.Approved
Aminohippuric acidThe serum concentration of Dasatinib can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Dasatinib.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Dasatinib.Approved
AmiodaroneThe serum concentration of Dasatinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Dasatinib.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Dasatinib.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Dasatinib.Approved
AmsacrineThe serum concentration of Dasatinib can be increased when it is combined with Amsacrine.Approved
AnagrelideDasatinib may increase the anticoagulant activities of Anagrelide.Approved
AncrodDasatinib may increase the anticoagulant activities of Ancrod.Investigational
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Dasatinib.Approved
Antithrombin III humanDasatinib may increase the anticoagulant activities of Antithrombin III human.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Dasatinib.Investigational
ApixabanDasatinib may increase the anticoagulant activities of Apixaban.Approved
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Dasatinib.Approved, Investigational
AprepitantThe serum concentration of Dasatinib can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinDasatinib may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanDasatinib may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.Approved, Investigational
Arsenic trioxideDasatinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Dasatinib.Approved
AsenapineAsenapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Dasatinib.Approved, Withdrawn
AtazanavirThe serum concentration of Dasatinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Dasatinib can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Dasatinib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Dasatinib.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Dasatinib.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Dasatinib.Approved, Investigational
AzelastineDasatinib may increase the anticoagulant activities of Azelastine.Approved
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Dasatinib.Approved
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Dasatinib.Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Dasatinib.Investigational
BecaplerminDasatinib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Dasatinib.Approved
BenzocaineThe serum concentration of Dasatinib can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Dasatinib.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Dasatinib.Approved
BepridilThe serum concentration of Dasatinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostDasatinib may increase the anticoagulant activities of Beraprost.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dasatinib.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Dasatinib.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Dasatinib.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Dasatinib.Approved
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Dasatinib.Approved
BiperidenThe serum concentration of Dasatinib can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Dasatinib.Approved
BivalirudinDasatinib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Dasatinib can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Dasatinib.Approved, Investigational
BosentanThe serum concentration of Dasatinib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dasatinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dasatinib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Dasatinib.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Dasatinib.Approved
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Dasatinib.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Dasatinib.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Dasatinib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Dasatinib.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Dasatinib.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Dasatinib.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Dasatinib.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Dasatinib.Approved, Investigational
ButylphthalideDasatinib may increase the anticoagulant activities of Butylphthalide.Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Dasatinib.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Dasatinib.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Dasatinib.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Dasatinib.Approved
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Dasatinib.Approved, Nutraceutical
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dasatinib.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Dasatinib.Approved
CandesartanThe serum concentration of Dasatinib can be increased when it is combined with Candesartan.Approved
CangrelorDasatinib may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe serum concentration of Dasatinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Dasatinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Dasatinib.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dasatinib.Approved
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Dasatinib.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Dasatinib.Approved, Investigational
CaspofunginThe serum concentration of Dasatinib can be increased when it is combined with Caspofungin.Approved
CDX-110The risk or severity of adverse effects can be increased when Dasatinib is combined with CDX-110.Investigational
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Dasatinib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Dasatinib.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Dasatinib.Approved, Vet Approved
CeritinibThe serum concentration of Dasatinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Dasatinib.Withdrawn
CertoparinDasatinib may increase the anticoagulant activities of Certoparin.Approved
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Dasatinib.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Dasatinib.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Dasatinib.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Dasatinib.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ChlorpropamideThe serum concentration of Dasatinib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Dasatinib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Dasatinib.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Dasatinib.Approved, Nutraceutical
CholesterolThe serum concentration of Dasatinib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Dasatinib can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Dasatinib.Approved, Investigational
CilazaprilThe serum concentration of Dasatinib can be increased when it is combined with Cilazapril.Approved
CilostazolDasatinib may increase the anticoagulant activities of Cilostazol.Approved
CimetidineCimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Dasatinib.Approved
CiprofloxacinDasatinib may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Dasatinib.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dasatinib.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Dasatinib.Approved
Citric AcidDasatinib may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Dasatinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Dasatinib can be decreased when combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Dasatinib.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Dasatinib.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Dasatinib.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Dasatinib.Approved
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Dasatinib.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dasatinib.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Dasatinib.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Dasatinib.Approved
ClopidogrelDasatinib may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Dasatinib.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Dasatinib.Approved, Illicit
ClotrimazoleThe metabolism of Dasatinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Dasatinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Dasatinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dasatinib.Approved
CocaineThe serum concentration of Cocaine can be increased when it is combined with Dasatinib.Approved, Illicit
CodeineThe serum concentration of Codeine can be increased when it is combined with Dasatinib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dasatinib.Approved
ColforsinThe serum concentration of Dasatinib can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Dasatinib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dasatinib.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Dasatinib.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Dasatinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Dasatinib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Dasatinib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Dasatinib.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dasatinib.Approved
DabrafenibThe serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Dasatinib.Approved
DactinomycinThe serum concentration of Dasatinib can be increased when it is combined with Dactinomycin.Approved
DalteparinDasatinib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDasatinib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Dasatinib.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.Approved
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Dasatinib.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Dasatinib.Approved, Investigational
DarunavirThe serum concentration of Dasatinib can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Dasatinib.Approved
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Dasatinib.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dasatinib.Approved
DeferasiroxThe serum concentration of Dasatinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDasatinib may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Dasatinib.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dasatinib.Approved
DesipramineThe serum concentration of Dasatinib can be increased when it is combined with Desipramine.Approved
DesirudinDasatinib may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Dasatinib.Approved
DesloratadineThe serum concentration of Dasatinib can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Dasatinib.Approved
DexamethasoneThe serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
DextranDasatinib may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Dasatinib may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Dasatinib may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Dasatinib may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Dasatinib.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Dasatinib.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Dasatinib.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Dasatinib.Approved, Vet Approved
DicoumarolDasatinib may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dasatinib.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Dasatinib.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Dasatinib.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Dasatinib.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Dasatinib.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dasatinib.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Dasatinib.Approved
DipyridamoleDasatinib may increase the anticoagulant activities of Dipyridamole.Approved
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Dasatinib.Approved
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Dasatinib.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Dasatinib.Approved
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Dasatinib.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Dasatinib.Approved
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Dasatinib.Approved
DoxazosinThe serum concentration of Dasatinib can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dasatinib.Approved, Investigational
DoxycyclineThe metabolism of Dasatinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Dasatinib.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Dasatinib.Approved
DroperidolDasatinib may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Dasatinib.Approved, Investigational
Edetic AcidDasatinib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dasatinib.Approved
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Dasatinib.Approved, Investigational
ElbasvirThe serum concentration of Dasatinib can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Dasatinib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Dasatinib.Approved
EltrombopagThe serum concentration of Dasatinib can be increased when it is combined with Eltrombopag.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Dasatinib.Approved
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Dasatinib.Approved, Vet Approved
EnoxaparinDasatinib may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Dasatinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineEpinastine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Dasatinib.Approved
eplivanserineDasatinib may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolDasatinib may increase the anticoagulant activities of Epoprostenol.Approved
EptifibatideDasatinib may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Dasatinib.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Dasatinib.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Dasatinib.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Dasatinib.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Dasatinib.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Dasatinib.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dasatinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Dasatinib.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Dasatinib.Approved
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Dasatinib.Approved
EstriolThe serum concentration of Dasatinib can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Dasatinib.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Dasatinib.Approved
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Dasatinib.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Dasatinib.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dasatinib.Approved
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.Approved
Ethyl biscoumacetateDasatinib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Dasatinib.Approved, Illicit
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Dasatinib.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Dasatinib.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Dasatinib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Dasatinib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dasatinib.Approved
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Dasatinib.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dasatinib.Approved
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Dasatinib.Approved
FamotidineFamotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Dasatinib.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Dasatinib.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Dasatinib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.Approved
FexofenadineThe serum concentration of Dasatinib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dasatinib.Approved
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Dasatinib.Approved
FingolimodDasatinib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideDasatinib may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Dasatinib.Approved
FluconazoleThe metabolism of Dasatinib can be decreased when combined with Fluconazole.Approved
FluindioneDasatinib may increase the anticoagulant activities of Fluindione.Investigational
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Dasatinib.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Dasatinib.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Dasatinib.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Dasatinib.Approved, Vet Approved
FlupentixolDasatinib may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Dasatinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Dasatinib.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Dasatinib.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Dasatinib.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Dasatinib.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Dasatinib.Approved
FluvoxamineThe metabolism of Dasatinib can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxDasatinib may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumDasatinib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Dasatinib.Approved
FosaprepitantThe serum concentration of Dasatinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Dasatinib can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Dasatinib.Approved, Investigational
Fusidic AcidThe serum concentration of Dasatinib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Dasatinib is combined with G17DT.Investigational
GabexateDasatinib may increase the anticoagulant activities of Gabexate.Investigational
Gadobenic acidDasatinib may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Dasatinib.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Dasatinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dasatinib.Approved
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Dasatinib.Approved
GemifloxacinDasatinib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Dasatinib can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Dasatinib is combined with GI-5005.Investigational
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Dasatinib.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Dasatinib.Approved
GlycerolThe serum concentration of Dasatinib can be increased when it is combined with Glycerol.Experimental
GoserelinDasatinib may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Dasatinib can be increased when it is combined with Gramicidin D.Approved
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Dasatinib.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dasatinib.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Dasatinib.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Dasatinib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Dasatinib.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Dasatinib.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Dasatinib.Approved, Vet Approved
HeparinDasatinib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Dasatinib.Approved
HirulogDasatinib may increase the anticoagulant activities of Hirulog.Experimental
Histamine PhosphateThe serum concentration of Histamine Phosphate can be increased when it is combined with Dasatinib.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Dasatinib.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Dasatinib.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Dasatinib.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Dasatinib.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Dasatinib.Approved
IbudilastDasatinib may increase the anticoagulant activities of Ibudilast.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dasatinib.Approved
IbutilideDasatinib may increase the QTc-prolonging activities of Ibutilide.Approved
Icosapent ethylDasatinib may increase the anticoagulant activities of Icosapent ethyl.Approved, Nutraceutical
IdelalisibThe serum concentration of Dasatinib can be increased when it is combined with Idelalisib.Approved
idraparinuxDasatinib may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilDasatinib may increase the anticoagulant activities of Ifenprodil.Approved, Withdrawn
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Dasatinib.Approved
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Dasatinib.Approved
IloprostDasatinib may increase the anticoagulant activities of Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dasatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Dasatinib.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Dasatinib.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Dasatinib.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Dasatinib.Approved
IndinavirThe serum concentration of Dasatinib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Dasatinib can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Dasatinib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Dasatinib is combined with INGN 225.Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Dasatinib.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Dasatinib.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Dasatinib.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Dasatinib.Approved
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Dasatinib.Approved
ItraconazoleThe serum concentration of Dasatinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Dasatinib.Approved
IvacaftorThe serum concentration of Dasatinib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Dasatinib.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Dasatinib.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Dasatinib.Approved
KetamineThe serum concentration of Ketamine can be increased when it is combined with Dasatinib.Approved, Vet Approved
KetanserinDasatinib may increase the anticoagulant activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Dasatinib.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Dasatinib.Approved
KetoconazoleThe serum concentration of Dasatinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dasatinib.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dasatinib.Approved, Investigational
LansoprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Dasatinib.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Dasatinib.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dasatinib.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Dasatinib is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dasatinib.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Dasatinib.Approved
LepirudinDasatinib may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Dasatinib.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Dasatinib.Approved, Investigational
LeuprolideDasatinib may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dasatinib.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Dasatinib.Approved
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Dasatinib.Approved
LevofloxacinDasatinib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Dasatinib.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Dasatinib.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Dasatinib.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Dasatinib.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Dasatinib.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Dasatinib.Approved
LiothyronineThe serum concentration of Dasatinib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Dasatinib can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Dasatinib can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe serum concentration of Lisuride can be increased when it is combined with Dasatinib.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Dasatinib.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Dasatinib.Approved
LopinavirThe serum concentration of Dasatinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Dasatinib.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Dasatinib.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Dasatinib.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Dasatinib.Approved, Investigational
LuliconazoleThe serum concentration of Dasatinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dasatinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Dasatinib.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Dasatinib.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Dasatinib.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Dasatinib.Approved, Investigational
MaprotilineThe serum concentration of Dasatinib can be increased when it is combined with Maprotiline.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Dasatinib.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Dasatinib.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Dasatinib.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Dasatinib.Approved
Megestrol acetateThe serum concentration of Dasatinib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Dasatinib.Approved, Vet Approved
MeprobamateThe serum concentration of Dasatinib can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Dasatinib.Withdrawn
MethadoneThe serum concentration of Methadone can be increased when it is combined with Dasatinib.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Dasatinib.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dasatinib.Approved
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Dasatinib.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Dasatinib.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Dasatinib.Approved
MetiamideMetiamide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MetoprololThe serum concentration of Dasatinib can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Dasatinib.Approved
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Dasatinib.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Dasatinib.Approved
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Dasatinib.Withdrawn
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Dasatinib.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Dasatinib.Approved, Investigational
MilrinoneDasatinib may increase the anticoagulant activities of Milrinone.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Dasatinib.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Dasatinib.Approved
MitomycinThe serum concentration of Dasatinib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Dasatinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Dasatinib can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Dasatinib.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Dasatinib.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Dasatinib.Approved, Investigational
MoxifloxacinDasatinib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dasatinib.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Dasatinib.Approved
NadroparinDasatinib may increase the anticoagulant activities of Nadroparin.Approved
NafamostatDasatinib may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Dasatinib can be decreased when it is combined with Nafcillin.Approved
NaftopidilDasatinib may increase the anticoagulant activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dasatinib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Dasatinib.Approved, Vet Approved
NaltrexoneThe serum concentration of Dasatinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Dasatinib can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Dasatinib.Approved, Investigational
NCX 4016Dasatinib may increase the anticoagulant activities of NCX 4016.Investigational
NefazodoneThe serum concentration of Dasatinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dasatinib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Dasatinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Dasatinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Dasatinib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Dasatinib.Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Dasatinib.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Dasatinib.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Dasatinib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Dasatinib.Approved
NimesulideDasatinib may increase the anticoagulant activities of Nimesulide.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Dasatinib.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dasatinib.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Dasatinib.Approved
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Dasatinib.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Dasatinib.Approved
NitroaspirinDasatinib may increase the anticoagulant activities of Nitroaspirin.Investigational
NizatidineNizatidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Dasatinib.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Dasatinib.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Dasatinib.Approved
OfloxacinDasatinib may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Dasatinib.Approved
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Dasatinib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dasatinib.Approved
OmeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Dasatinib.Approved
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Dasatinib.Approved
OsimertinibThe serum concentration of Dasatinib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Dasatinib.Approved
OtamixabanDasatinib may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Dasatinib.Approved
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Dasatinib.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Dasatinib.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Dasatinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.Approved, Vet Approved
PalbociclibThe serum concentration of Dasatinib can be increased when it is combined with Palbociclib.Approved
PaliperidoneDasatinib may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Dasatinib can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Dasatinib.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Dasatinib.Approved, Investigational
PantoprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Pantoprazole.Approved
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Dasatinib.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Dasatinib.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Dasatinib.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Dasatinib.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Dasatinib.Approved
ParoxetineThe serum concentration of Dasatinib can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dasatinib.Approved
Peginterferon alfa-2bThe serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Dasatinib.Approved
PentobarbitalThe serum concentration of Dasatinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateDasatinib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineDasatinib may increase the anticoagulant activities of Pentoxifylline.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Dasatinib.Approved
PerflutrenDasatinib may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe serum concentration of Pergolide can be increased when it is combined with Dasatinib.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Dasatinib.Approved
PerindoprilThe serum concentration of Dasatinib can be increased when it is combined with Perindopril.Approved
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Dasatinib.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Dasatinib.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Dasatinib.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Dasatinib.Withdrawn
PhenindioneDasatinib may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Dasatinib can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Dasatinib.Approved
PhenprocoumonDasatinib may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Dasatinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Dasatinib.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dasatinib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dasatinib.Approved
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Dasatinib.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Dasatinib.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Dasatinib.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dasatinib.Approved
Platelet Activating FactorThe serum concentration of Dasatinib can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Dasatinib.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Dasatinib.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Dasatinib.Approved
PosaconazoleThe serum concentration of Dasatinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be increased when it is combined with Dasatinib.Approved, Nutraceutical
PrasugrelDasatinib may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Dasatinib.Approved
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Dasatinib.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Dasatinib.Approved, Vet Approved
PrazosinThe serum concentration of Dasatinib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Dasatinib.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Dasatinib.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Dasatinib.Approved
PrimidoneThe serum concentration of Dasatinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Dasatinib can be increased when it is combined with Probenecid.Approved
ProcainamideDasatinib may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Dasatinib.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Dasatinib.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Dasatinib.Approved, Vet Approved
PromethazineThe serum concentration of Dasatinib can be increased when it is combined with Promethazine.Approved
PropacetamolDasatinib may increase the hepatotoxic activities of Propacetamol.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Dasatinib.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Dasatinib.Approved, Investigational
Protein CDasatinib may increase the anticoagulant activities of Protein C.Approved
Protein S humanDasatinib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDasatinib may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Dasatinib can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dasatinib.Approved
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Dasatinib.Approved
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Dasatinib.Approved, Illicit
QuercetinThe serum concentration of Dasatinib can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Dasatinib.Approved
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Dasatinib.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Dasatinib.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Dasatinib.Approved
RabeprazoleThe serum concentration of Dasatinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Dasatinib is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Dasatinib.Approved
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Dasatinib.Approved, Investigational
RamatrobanDasatinib may increase the anticoagulant activities of Ramatroban.Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Dasatinib.Approved, Investigational
RanitidineRanitidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dasatinib.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Dasatinib.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Dasatinib.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Dasatinib.Approved, Investigational
ReserpineThe serum concentration of Dasatinib can be decreased when it is combined with Reserpine.Approved
ResveratrolDasatinib may increase the anticoagulant activities of Resveratrol.Experimental, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Dasatinib.Approved
ReviparinDasatinib may increase the anticoagulant activities of Reviparin.Approved
RidogrelDasatinib may increase the anticoagulant activities of Ridogrel.Approved
RifabutinThe serum concentration of Dasatinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Dasatinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Dasatinib can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dasatinib.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Dasatinib.Approved
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Dasatinib.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Dasatinib.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Dasatinib.Approved, Investigational
RitonavirThe serum concentration of Dasatinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanDasatinib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Dasatinib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Dasatinib.Approved
RolapitantThe serum concentration of Dasatinib can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Dasatinib.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Dasatinib.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Dasatinib.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dasatinib.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Dasatinib.Approved
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Dasatinib.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Dasatinib.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Dasatinib.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Dasatinib.Approved
SaquinavirThe serum concentration of Dasatinib can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Dasatinib.Approved
SCH-530348Dasatinib may increase the anticoagulant activities of SCH-530348.Investigational
ScopolamineThe serum concentration of Dasatinib can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Dasatinib.Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Dasatinib.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Dasatinib.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Dasatinib.Approved
SevofluraneDasatinib may increase the anticoagulant activities of Sevoflurane.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Dasatinib.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dasatinib.Approved
SiltuximabThe serum concentration of Dasatinib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dasatinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Dasatinib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dasatinib.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Dasatinib.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Dasatinib.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dasatinib.Approved
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Dasatinib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Dasatinib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Dasatinib.Approved, Investigational
SotalolDasatinib may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dasatinib.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dasatinib.Experimental
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Dasatinib.Approved
SpironolactoneThe serum concentration of Dasatinib can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Dasatinib is combined with SRP 299.Investigational
SRT501Dasatinib may increase the anticoagulant activities of SRT501.Investigational
St. John's WortThe serum concentration of Dasatinib can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Dasatinib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Dasatinib can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Dasatinib can be decreased when it is combined with Streptozocin.Approved
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Dasatinib.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Dasatinib.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Dasatinib.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Dasatinib.Approved
SulfisoxazoleDasatinib may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideDasatinib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Dasatinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Dasatinib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Dasatinib.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Dasatinib.Approved
TacrineThe serum concentration of Dasatinib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dasatinib.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Dasatinib.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Dasatinib.Approved, Investigational
TAK-390MRThe serum concentration of Dasatinib can be decreased when it is combined with TAK-390MR.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Dasatinib.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Dasatinib.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Dasatinib.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Dasatinib.Experimental
Taurocholic AcidThe serum concentration of Dasatinib can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dasatinib.Approved
TelaprevirThe serum concentration of Dasatinib can be increased when it is combined with Telaprevir.Approved
TelavancinDasatinib may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Dasatinib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Dasatinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Dasatinib.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Dasatinib.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Dasatinib.Approved
TenofovirThe metabolism of Dasatinib can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Dasatinib can be increased when it is combined with Terazosin.Approved
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Dasatinib.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Dasatinib.Withdrawn
TeriflunomideThe serum concentration of Dasatinib can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneDasatinib may increase the anticoagulant activities of Tesmilifene.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Dasatinib.Approved, Investigational
TetrabenazineDasatinib may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Dasatinib.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Dasatinib is combined with TG4010.Investigational
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Dasatinib.Approved
ThioridazineDasatinib may increase the QTc-prolonging activities of Thioridazine.Approved
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Dasatinib.Approved
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Dasatinib.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Dasatinib.Approved
TiclopidineDasatinib may increase the anticoagulant activities of Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Dasatinib.Approved
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Dasatinib.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Dasatinib.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Dasatinib.Approved, Investigational
TirofibanDasatinib may increase the anticoagulant activities of Tirofiban.Approved
TocilizumabThe serum concentration of Dasatinib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDasatinib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Dasatinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dasatinib.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dasatinib.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Dasatinib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Dasatinib.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Dasatinib.Approved, Investigational
TranilastDasatinib may increase the anticoagulant activities of Tranilast.Approved, Investigational
TrapidilDasatinib may increase the anticoagulant activities of Trapidil.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Dasatinib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Dasatinib.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Dasatinib.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Dasatinib.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Dasatinib.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Dasatinib.Approved
TrifluoperazineThe serum concentration of Dasatinib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Dasatinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalDasatinib may increase the anticoagulant activities of Triflusal.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Dasatinib.Approved
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Dasatinib.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Dasatinib.Approved
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Dasatinib.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Dasatinib.Approved
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Dasatinib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dasatinib.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dasatinib.Approved
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Dasatinib.Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Dasatinib.Approved
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Dasatinib.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Dasatinib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dasatinib.Approved
VemurafenibThe serum concentration of Dasatinib can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Dasatinib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Dasatinib.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Dasatinib.Approved
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Dasatinib.Investigational
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Dasatinib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Dasatinib.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Dasatinib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dasatinib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Dasatinib.Approved
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Dasatinib.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Dasatinib.Approved
VorapaxarDasatinib may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Dasatinib.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Dasatinib.Approved
WarfarinDasatinib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDasatinib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Dasatinib may increase the anticoagulant activities of Ym150.Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Dasatinib.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Dasatinib.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Dasatinib.Approved
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Dasatinib.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Dasatinib.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Dasatinib.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Dasatinib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Dasatinib.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Dasatinib.Approved
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Dasatinib.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Dasatinib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Dasatinib.Approved
ZuclopenthixolDasatinib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceUS6596746
General References
  1. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [PubMed:17154512 ]
  2. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. [PubMed:16775234 ]
External Links
ATC CodesL01XE06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (237 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9852
Blood Brain Barrier-0.507
Caco-2 permeable-0.5638
P-glycoprotein substrateSubstrate0.6562
P-glycoprotein inhibitor IInhibitor0.5371
P-glycoprotein inhibitor IIInhibitor0.5425
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.7061
CYP450 2D6 substrateNon-substrate0.8152
CYP450 3A4 substrateSubstrate0.5704
CYP450 1A2 substrateNon-inhibitor0.5612
CYP450 2C9 inhibitorInhibitor0.8008
CYP450 2D6 inhibitorNon-inhibitor0.8358
CYP450 2C19 inhibitorInhibitor0.574
CYP450 3A4 inhibitorInhibitor0.7295
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8343
Ames testNon AMES toxic0.7185
CarcinogenicityNon-carcinogens0.7308
BiodegradationNot ready biodegradable0.9863
Rat acute toxicity2.4772 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8538
hERG inhibition (predictor II)Inhibitor0.718
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral100 mg
TabletOral140 mg/1
TabletOral140 mg
TabletOral20 mg/1
TabletOral20 mg
TabletOral50 mg/1
TabletOral50 mg
TabletOral70 mg/1
TabletOral70 mg
TabletOral80 mg/1
TabletOral80 mg
Tablet, film coatedOral100 mg
Tablet, film coatedOral140 mg
Tablet, film coatedOral20 mg
Tablet, film coatedOral50 mg
Tablet, film coatedOral70 mg
Tablet, film coatedOral80 mg
Prices
Unit descriptionCostUnit
Sprycel 100 mg tablet278.24USD tablet
Sprycel 50 mg tablet139.12USD tablet
Sprycel 70 mg tablet139.12USD tablet
Sprycel 20 mg tablet69.56USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2366932 No2009-08-252020-04-12Canada
US6596746 No2000-06-282020-06-28Us
US7125875 No2000-04-132020-04-13Us
US7153856 No2000-04-282020-04-28Us
US7491725 No2006-03-282026-03-28Us
US8680103 No2005-02-042025-02-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point280-286 °CNot Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0128 mg/mLALOGPS
logP2.77ALOGPS
logP3.82ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)8.49ChemAxon
pKa (Strongest Basic)7.22ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area106.51 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity133.08 m3·mol-1ChemAxon
Polarizability51.58 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • N-arylamide
  • Aminotoluene
  • Dialkylarylamine
  • Thiazolecarboxylic acid or derivatives
  • Thiazolecarboxamide
  • N-alkylpiperazine
  • Toluene
  • Halobenzene
  • Chlorobenzene
  • Aminopyrimidine
  • 2,5-disubstituted 1,3-thiazole
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Molecular Weight:
122871.435 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Piccaluga PP, Paolini S, Martinelli G: Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer. 2007 Sep 15;110(6):1178-86. [PubMed:17701954 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Sh3/sh2 adaptor activity
Specific Function:
Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including...
Gene Name:
SRC
Uniprot ID:
P12931
Molecular Weight:
59834.295 Da
References
  1. Kamath AV, Wang J, Lee FY, Marathe PH: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11. [PubMed:17429625 ]
  2. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG: Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5. [PubMed:17148760 ]
  3. Quintas-Cardama A, Kantarjian H, Cortes J: Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol. 2006 Dec;2(6):655-65. [PubMed:17155893 ]
  4. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. [PubMed:16397263 ]
  5. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005 Oct 15;65(20):9185-9. [PubMed:16230377 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the lig...
Gene Name:
EPHA2
Uniprot ID:
P29317
Molecular Weight:
108265.585 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
multitarget
General Function:
Sh2 domain binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antig...
Gene Name:
LCK
Uniprot ID:
P06239
Molecular Weight:
58000.15 Da
References
  1. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. [PubMed:17154512 ]
  2. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR a...
Gene Name:
YES1
Uniprot ID:
P07947
Molecular Weight:
60800.78 Da
References
  1. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE: Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006 Mar;168(3):962-72. [PubMed:16507911 ]
  2. Margutti S, Laufer SA: Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem. 2007 Aug;2(8):1116-40. [PubMed:17541990 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81. [PubMed:16397263 ]
  2. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91. Epub 2006 Jan 24. [PubMed:16434489 ]
  3. Dizdar O, Dede DS, Bulut N, Altundag K: Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. Breast Cancer Res Treat. 2008 Jan;107(2):303. Epub 2007 Mar 10. [PubMed:17351742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Vascular endothelial growth factor binding
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:
PDGFRB
Uniprot ID:
P09619
Molecular Weight:
123966.895 Da
References
  1. Zhang Z, Meier KE: New assignments for multitasking signal transduction inhibitors. Mol Pharmacol. 2006 May;69(5):1510-2. Epub 2006 Feb 23. [PubMed:16497876 ]
  2. Chen Z, Lee FY, Bhalla KN, Wu J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006 May;69(5):1527-33. Epub 2006 Jan 25. [PubMed:16436588 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transcription factor activity, sequence-specific dna binding
Specific Function:
Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription.
Gene Name:
STAT5B
Uniprot ID:
P51692
Molecular Weight:
89865.35 Da
References
  1. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K: Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. [PubMed:17020995 ]
  2. Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R: Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007 Apr;6(4):1400-5. [PubMed:17431118 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
multitarget
General Function:
Receptor binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (...
Gene Name:
ABL2
Uniprot ID:
P42684
Molecular Weight:
128341.935 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
multitarget
General Function:
Protein tyrosine kinase activity
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associa...
Gene Name:
FYN
Uniprot ID:
P06241
Molecular Weight:
60761.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. [PubMed:20072833 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  2. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12. [PubMed:18556438 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  3. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3348-54. doi: 10.1182/blood-2007-10-116236. Epub 2008 Jul 31. [PubMed:18669873 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
Comments
comments powered by Disqus
Drug created on May 08, 2007 18:32 / Updated on December 07, 2016 02:37